Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicines Patent Pool Welcomes WHO’s Updated Essential Medicines List

As WHO Calls On Originators To License Their Medicines To MPP

Executive Summary

The Medicines Patent Pool has welcomed the WHO’s updated essential medicines list that includes four medicines already licensed to the MPP, of which two were developed through MPP licensees. The WHO’s updated list includes SGLT2 inhibitors – oral medications used to lower blood glucose levels – for which the MPP and the International Diabetes Federation have committed to improve affordable access in low- and middle-income countries. 

You may also be interested in...



US Bill Would Create Emergency API Stockpile

US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.

Glenmark Launches Tiotropium DPI In Spain

India’s Glenmark has announced the launch of Tavulus, its generic version of Boehringer Ingelheim’s Spiriva Handihaler, in Spain. The company is also looking to launch its tiotropium bromide dry powder inhaler in other key European markets. 

Amgen Urges Balance In US Biosimilars Policy

Amgen’s recent study on biosimilars trends has outlined the importance of US policy in the success of the biosimilars marketplace, insisting on the importance of increased competition and effective reimbursement and education policies. But with interests in innovative biologics as well as biosimilars, the company has also emphasized that pro-biosimilars policies must not stifle innovation and compromise free competition.

Topics

UsernamePublicRestriction

Register

GB151312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel